Adage Capital Partners Gp, L.L.C. Arbutus Biopharma Corp Transaction History
Adage Capital Partners Gp, L.L.C.
- $51 Billion
- Q1 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 3,000,000 shares of ABUS stock, worth $9.39 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
3,000,000Holding current value
$9.39 Million% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding ABUS
# of Institutions
130Shares Held
82.2MCall Options Held
4.82MPut Options Held
546K-
Whitefort Capital Management, LP New York, NY12.9MShares$40.3 Million24.48% of portfolio
-
Black Rock Inc. New York, NY10.4MShares$32.6 Million0.0% of portfolio
-
Morgan Stanley New York, NY8.83MShares$27.6 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY7.84MShares$24.5 Million10.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.99MShares$18.7 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $469M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...